BlinkLab Limited
Research BlinkLab Limited (BB1.AX) on Bullrun: market cap AUD 104.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBB1.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyAUD
- Market capAUD 104.91M
- Financial periodFY2026
- Net income-AUD 7.22M
- Free cash flow-AUD 7.54M
Valuation Snapshot
latest market cap is AUD 104.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 7.22M | -AUD 7.54M | n/a | n/a | AUD 7.88M | AUD 388.66K | AUD 19.50M |
| FY2025 | n/a | -AUD 5.71M | -AUD 4.30M | n/a | -0.06 | AUD 8.71M | AUD 128.98K | AUD 8.97M |
| FY2024 | n/a | -AUD 1.75M | -AUD 1.90M | n/a | n/a | AUD 3.02M | AUD 168.69K | AUD 6.48M |
| FY2023 | n/a | -AUD 676.38K | -AUD 556.42K | n/a | -0.01 | AUD 50.06K | AUD 15.23K | AUD 40.72K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 104.91M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About BlinkLab Limited
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BlinkLab Limited's market cap?
BlinkLab Limited's market capitalization is AUD 104.91M.
What does BlinkLab Limited do?
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption.